HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma

Lin Shi-Ming; Lu Sheng-Nan; Chen Ping-Tsung; Jeng Long-Bin; Chen Shinn-Cherng; Hu Chi-Tan; Yang Sien-Sing; Le Berre Marie-Aude; Liu Xuan; Mitchell David Y.; Prins Klaas; Grevel Joachim; Pena Carol A. E.; Meinhardt Gerold

首页> 外文期刊>Hepatology international >HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma

【24h】

HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma

机译：HATT：IV期，单臂，索拉非尼患者患有先进的肝细胞癌患者的单臂开放式研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Sorafenib significantly improves survival in patients with advanced hepatocellular carcinoma (HCC). This phase IV study assessed sorafenib efficacy/safety in Taiwanese patients with advanced HCC and Child-Pugh A status.

机译：索拉非尼明显改善肝细胞癌（HCC）患者的存活。该第四级研究在台湾患者高级HCC和Child-Pugh患者中评估了Sorafenib疗效/安全性。

著录项

来源
《Hepatology international》 |2017年第2期|共10页
作者
Lin Shi-Ming; Lu Sheng-Nan; Chen Ping-Tsung; Jeng Long-Bin; Chen Shinn-Cherng; Hu Chi-Tan; Yang Sien-Sing; Le Berre Marie-Aude; Liu Xuan; Mitchell David Y.; Prins Klaas; Grevel Joachim; Pena Carol A. E.; Meinhardt Gerold;
展开▼
作者单位

Linkou &

Taipei Chang Gung Mem Hosp Chang Gung Un Div Hepatol Dept Gastroenterol &

Hepatol 5;

Kaohsiung Chang Gung Mem Hosp Div Hepatogastroenterol 100 Tapei Rd Kaohsiung 833 Taiwan;

Chiayi Chang Gung Mem Hosp Div Hematol &

Oncol 6 W Sec Chia Pu Rd Chiayi 613 Taiwan;

China Med Univ Hosp Organ Transplantat Ctr Taichung 404 Taiwan;

Kaohsiung Med Univ Hosp Div Hepatobiliary Pancreat Med 100 Tzyou 1st Rd Kaohsiung 807 Taiwan;

Tzu Chi Univ Buddhist Tzu Chi Gen Hosp Div Hepatogastroenterol 707 Sec 3 Chung Yang Rd Hualian;

Cathay Gen Hosp Ctr Liver 280 Sec 4 Jen Ai Rd Taipei Taiwan;

Bayer HealthCare Pharmaceut Clin Stat Med Affairs Bldg C2 1-11 220 Ave Rech F-59120 Loos France;

Bayer HealthCare Co Ltd Global Clin Dev Bayer Ctr 18F Tower B 27 Dong San Huan North Rd Beijing;

Mitchell Pharmaceut Consulting 1188 Hawk Ridge Rd Lafayette CO 80026 USA;

qPharmetra LLC Kwakkenbergweg 39 NL-6523 MK Nijmegen Netherlands;

BAST Inc Ltd 7 Wellingtonia Close Shepshed LE12 9FB England;

Bayer Healthcare Pharmaceut Clin Sci 100 Bayer Rd Whippany NJ USA;

Bayer Healthcare Pharmaceut Global Clin Dev Oncol 100 Bayer Rd Whippany NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
Sorafenib; Advanced hepatocellular carcinoma; Metastatic hepatocellular carcinoma; Taiwanese patients; Overall survival; Time to progression;

机译：索拉芬皮;晚期肝细胞癌;转移性肝细胞癌;台湾患者;总体生存;进展时间;

相似文献

外文文献
中文文献
专利

1. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma [J] . Shi-Ming Lin, Sheng-Nan Lu, Ping-Tsung Chen, Hepatology international . 2017,第2期

机译：HATT：索拉非尼在台湾晚期肝细胞癌患者中进行的IV期单臂开放标签研究
2. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma [J] . Lin Shi-Ming, Lu Sheng-Nan, Chen Ping-Tsung, Hepatology international . 2017,第2期

机译：HATT：IV期，单臂，索拉非尼患者患有先进的肝细胞癌患者的单臂开放式研究
3. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study [J] . Vichien SRIMUNINNIMIT, Virote SRIURANPONG Suthida SUWANVECHO Asia-Pacific journal of clinical oncology . 2014,第3期

机译：索拉非尼联合吉西他滨治疗晚期肝细胞癌的疗效和安全性：一项多中心，开放标签，单组II期研究
4. Diffusion-weighted MR imaging of advanced hepatocellular carcinoma treated with the oral multikinase inhibitor Sorafenib [C] . C. Schraml, N.F. Schwenzer, H. Rempp, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：口服多激酶抑制剂索拉非尼治疗晚期肝癌的扩散加权MR成像
5. Poly(lactide-co-glycolide) Microspheres for Localized, Magnetic Resonance Imaging Monitored, Transcatheter Delivery of Sorafenib to Hepatocellular Carcinoma. [D] . Chen, Jeane. 2015

机译：聚（丙交酯-共-乙交酯）微球体用于局部监测，磁共振成像监测，索拉非尼经导管输送至肝细胞癌。
6. A multicentre open-label phase-I/randomised phase-II study to evaluate safety pharmacokinetics and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [O] . D. H. Palmer, Y. T. Ma, M. Peck-Radosavljevic, 2018

机译：一项多中心开放标签I期/随机II期研究评估nintedanib与sorafenib在欧洲晚期肝细胞癌患者中的安全性药代动力学和疗效
7. A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma [O] . Devalingam Mahalingam, Julio Peguero, Putao Cen, 2019

机译：MIPSAGARGIN（G-202）的II期，多中心，单臂研究作为索拉非尼治疗患者患者进行渐进式晚期肝细胞癌的二线治疗

HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅